Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation

BACKGROUND: We designed the study to investigate whether methotrexate, doxorubicin, and cisplatinum (MAP) chemotherapy strategy was still the preferred option for the survival of osteosarcoma patients. METHOD: We collected some trials of osteosarcoma to make a meta-analysis first. Then, we retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Dapeng, Zhang, Shuisheng, Feng, Alei, Xu, Deguo, Zhu, Qingshan, Mao, Yantao, Zhao, Yi, Lv, Yajuan, Han, Cuiping, Liu, Rujun, Tian, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531127/
https://www.ncbi.nlm.nih.gov/pubmed/31083238
http://dx.doi.org/10.1097/MD.0000000000015582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531127/
https://www.ncbi.nlm.nih.gov/pubmed/31083238
http://dx.doi.org/10.1097/MD.0000000000015582

Ejemplares similares